Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that Equisetum debile extracts, particularly the ethyl acetate fraction, may offer natural cosmeceutical benefits for treating hyperpigmentation, delaying skin aging, and remediating hair loss due to androgenic alopecia.

This study reports two cases of alopecia areata that responded to the antihistamine fexofenadine.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

In this case report, researchers observed hair repigmentation in a man with metastatic renal cell carcinoma during treatment with axitinib, marking the first documented instance of this effect with axitinib without the use of hair dyes or other medications.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

This study concluded that 16β-methyl-17α-benzoyloxypregnen-4-en-3,20-dione may be a promising treatment for androgen-dependent diseases and epilepsy due to its antioxidant effects and impact on GABAergic and serotonergic metabolism in rats.

This study found that daily use of an emollient PLUS containing ADE-G1 significantly reduced xerosis severity and improved quality of life in cancer patients, regardless of their initial xerosis severity or cancer treatment.

In this study, EDA-A2 transgenic mice exhibited multifocal myodegeneration dependent on XEDAR, suggesting a potential role for XEDAR in skeletal muscle homeostasis.

In this study, behavioral disturbances were commonly observed with levetiracetam, while somnolence was frequently reported with oxcarbazepine among patients with refractory epilepsy.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study investigated the integration of crystal engineering and microneedle technology for androgenetic alopecia treatment, finding that microneedles loaded with newly developed Kopexil multicomponent crystals reduced drug diffusion rates in vitro compared to standard formulations.

This study found that erythrocyte-anchored CPA-encapsulated nanoparticles improved the delivery and accumulation of Cepharanthine in the lungs, enhancing its effectiveness in treating acute lung injury by reducing inflammatory responses.

This study found that the evodiamine derivative 2-16 exhibited the highest antitumor activity and a broad spectrum of activity against various human cancer cell lines, with improved solubility.

This study observed variable therapeutic responses in dogs with Alopecia X, with some showing complete hair regrowth while others did not, following similar treatments including orchiectomy and supplementation.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study concluded that two exemestane preparations are bioequivalent, using a high-performance liquid chromatographic mass spectrometric method to measure concentrations in human plasma.

This study found that a cream containing 20% broad bean extract may reduce axillary hair growth, but only some outcomes were statistically significant compared to placebo.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This study found that in rats, combined treatment with finasteride and doxazosin altered epithelial cell behavior and matrix metalloproteinases activity, suggesting effects possibly mediated by TGF-β1 and androgen pathways.

In this study, ethyl acetate fraction of Eclipta alba was found to inhibit adipogenesis and reduce dyslipidemia in hamsters, suggesting potential as an herbal treatment for obesity.

Among men with androgenetic alopecia, this study found that taking 5 mg of KX-826 twice daily significantly increased hair count compared to a placebo, with the treatment being well-tolerated and no serious adverse effects reported.

This study found that certain molecular quantum descriptors can be directly correlated with the biological activity of benzo[c]quinolizin-3-ones, potentially aiding in the identification and design of active compounds.

This study found that fremanezumab was effective in reducing migraine headache days by at least 50% for the majority of patients with high-frequency episodic or chronic migraine who had failed previous treatments.

This study demonstrated that benzothiazepines, such as diltiazem and JTV-519, exert anxiolytic-like effects through allopregnanolone biosynthesis in mice, similar to carbamazepine.

This study used machine learning to identify FDA-approved drugs afatinib, neratinib, and zanubrutinib as potential KRASG12C inhibitors for resistant non-small-cell lung cancer, highlighting the potential of AI in drug repurposing.

This study found that in mouse models, the novel NF-κB inhibitor DHMEQ improved symptoms of atopic dermatitis as effectively as tacrolimus or betamethasone.